Phase 1Completed

Pharmacokinetic and Safety Study of Cenicriviroc and Pioglitazone, When Dosed Alone or in Combination

A Phase 1, Multiple-Dose, Open-Label, Randomized, Crossover Study in Healthy Subjects to Assess the Effect of Pioglitazone (PGZ) on the Pharmacokinetics (PK) of Cenicriviroc Mesylate (CVC) and the Effect of CVC on the PK of PGZ

Sponsor
Tobira Therapeutics, Inc. (Industry)
Enrollment
20 enrolled
Conditions
Healthy
Interventions
Cenicriviroc; Pioglitazone
Ages
adults
Registry
NCT02342067

Full record on ClinicalTrials.gov

From the registry

A single center, open-label, fixed sequence study to evaluate the pharmacokinetics (PK) of Cenicriviroc (CVC) administered with and without Pioglitazone (PGZ), and to evaluate the PK of PGZ administered with and without CVC.

Primary outcomes

  • Pharmacokinetic Assessment of CVC, as measured by Cmax, Cmin and AUC
  • Pharmacokinetic Assessment of PGZ, as measured by Cmax, Cmin and AUC

History

  1. Last registry update

  2. Study completion

  3. Primary completion

  4. Registered

  5. Started